Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib
The Kaohsiung Journal of Medical Sciences · 07.05.2026
DOI: 10.1002/kjm2.70230 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, online erschienen am 07.05.2026. Verfasst von Cheng-Wei Kuo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Divison of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on serum albumin, lymphocyte count, and body weight. Patients were classified into high and low groups for each index. Multivariate models were used to assess their prognostic value for progression‐free survival (PFS) and overall survival (OS). Higher PNI (cut‐off: 45) and GNRI (cut‐off: 98) scores were associated with significantly better outcomes: the high PNI and low PNI groups achieved median PFS of 7.5 vs. 4.0 months ( p = 0.002) and OS of 19.3 vs. 9.8 months ( p < 0.001), respectively. Similarly, the high GNRI and low GNRI groups achieved median PFS of 7.3 versus 4.7 months ( p = 0.001) and OS of 21 versus 9.8 months ( p < 0.001), respectively. Patients with higher indices also had higher objective response rates, lower rates of severe treatment‐related adverse events, and were more likely to receive posttreatment therapies. The PNI (hazard ratio [HR]: 0.678, p = 0.018), GNRI (HR: 0.679, p = 0.031), and the combined indices (HR: 0.655, p = 0.013) independently demonstrated prognostic value for mortality in multivariate models. PNI and GNRI, both individually and in combination, are simple yet powerful tools that predict survival and treatment tolerance in patients with HCC receiving lenvatinib. Routine assessment of these indices may enhance patient stratification and guide therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Divison of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan.
- Division of Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan.
ORCID-Profile: Jing-Houng Wang, Sheng-Nan Lu, Chao-Hung Hung, Chien-Hung Chen
Zitieren
APA
Kuo, C. W., Tai, W. C., Chen, Y. H., Tsai, M. C., Wang, J. H., Lu, S. N., Hu, T. H., Hung, C. H., Chen, C. H., & Kuo, Y. H. (2026). Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70230
Vancouver
Kuo CW, Tai WC, Chen YH, Tsai MC, Wang JH, Lu SN, et al. Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib. The Kaohsiung Journal of Medical Sciences. 2026. doi:10.1002/kjm2.70230
BibTeX
@article{Kuo2026,
author = {Kuo, Cheng-Wei and Tai, Wei-Chen and Chen, Yen-Hao and Tsai, Ming-Chao and Wang, Jing-Houng and Lu, Sheng-Nan and Hu, Tsung-Hui and Hung, Chao-Hung and Chen, Chien-Hung and Kuo, Yuan-Hung},
title = {Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2026},
doi = {10.1002/kjm2.70230}
}
EUVIMED